Kejal Kantarci, Nirubol Tosakulwong, Timothy G Lesnick, Samantha M Zuk, Val J Lowe, Julie A Fields, Jeffrey L Gunter, Matthew L Senjem, Megan L Settell, Carey E Gleason, Lynne T Shuster, Kent R Bailey, N Maritza Dowling, Sanjay Asthana, Clifford R Jack, Walter A Rocca, Virginia M Miller
OBJECTIVE: The effects of 2 frequently used formulations of menopausal hormone therapy (mHT) on brain structure and cognition were investigated 3 years after the end of a randomized, placebo-controlled trial in recently menopausal women with good cardiovascular health. METHODS: Participants (aged 42-56 years; 5-36 months past menopause) were randomized to one of the following: 0.45 mg/d oral conjugated equine estrogen (oCEE); 50 μg/d transdermal 17β-estradiol (tE2); or placebo pills and patch for 4 years...
April 17, 2018: Neurology